Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Recommendations did not agree on the safety of using disease-modifying antirheumatic drugs in RA patients with cancer, except for the contraindication of tumor necrosis factor inhibitors in patients at risk for lymphoma.
|
30821928 |
2020 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, the tumor necrosis factor receptor superfamily cluster of differentiation 30 (CD30) has been thought to be implicated in malignant cells in organs affected by Hodgikin lymphoma or in a prognostic marker of diffuse large B cell lymphoma.
|
31335688 |
2019 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Only four studies found a significant association of anti-TNF drug with lymphoma or groups of cancers including lymphoma.
|
30941038 |
2019 |
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The tumor necrosis factor receptor superfamily member HVEM is one of the most frequently mutated surface proteins in germinal center (GC)-derived B cell lymphomas.
|
31204070 |
2019 |
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
TNFα antagonists may also be associated with an increased risk of lymphoma, especially when combined with thiopurines.
|
31322018 |
2019 |
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Anti-tumour Necrosis Factor Alpha Agents: A Systematic Review and Meta-analysis.
|
29762681 |
2018 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, spreading of ADAM10 activity due to ExoV can result in the release of cytokines, like TNFα, a lymphoma growth factor, or soluble molecules, like sMICA or sCD30, that potentially interfere with host immune surveillance or immunotherapy.
|
29721369 |
2018 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
This case suggests a potential relationship between immunosuppression with anti-TNFα medication, and increased risk for lymphoma, especially in patients with underlying rheumatologic disorders and especially in patients with suspected chronic refractory uveitis.
|
29954352 |
2018 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.
|
29114832 |
2017 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, even if meta-analysis of randomized controlled trials and of registries have not demonstrated to date an increased risk of lymphoma with anti-TNF, cautious must be pursued concerning this possible side effect in patients with long-term anti-TNF exposure.
|
28214146 |
2017 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Studies using better measures of adiposity are needed to further investigate the interactions between obesity and TNF-308G>A in the pathogenesis of lymphoma.
|
25962811 |
2015 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Doxorubicin resistant Dalton's lymphoma is susceptible to dendritic cell derived TNF-α upon stimulation with the STAT3 inhibitor cucurbitacin-I, which downregulates STAT3 and other survival molecules.
|
26255115 |
2015 |
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
B-cell activating factor-receptor specific activation of tumor necrosis factor receptor associated factor 6 and the phosphatidyl inositol 3-kinase pathway in lymphoma B cells.
|
24206092 |
2014 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We show that: i) lymph-node mesenchymal stromal cells of non-Hodgkin's lymphoma inhibit NKG2D-mediated lymphoid cell killing, but not rituximab-induced antibody-dependent cell-mediated cytotoxicity, exerted by Vδ2 T lymphocytes; ii) pre-treatment of mesenchymal stromal cells with the aminobisphosphonates pamidronate or zoledronate can rescue lymphoma cell killing via NKG2D; iii) this is due to inhibition of transforming growth factor-β and increase in interleukin-15 production by mesenchymal stromal cells; iv) aminobisphosphonate-treated mesenchymal stromal cells drive Vδ2 T-lymphocyte differentiation into effector memory T cells, expressing the Thelper1 cytokines tumor necrosis factor-α and interferon-γ.
|
24162786 |
2014 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We previously demonstrated that the downregulation of Casitas B-lineage lymphoma (c-Cbl) can sensitize tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in two different ways.
|
23306613 |
2013 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Roscovitine sensitizes leukemia and lymphoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
|
22830613 |
2013 |
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The soluble form of CD30 (sCD30), a member of tumor necrosis factor receptor superfamily, has been used as a marker of disease activity in various lymphomas.
|
21181928 |
2011 |
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Evidence for lymphoma developing as a result of treatment with methotrexate or Tumour Necrosis Factor Antagonists for autoimmune entities will also be reviewed.
|
18456377 |
2008 |
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
As not all the patients with infection or lymphoma have secondary HLH, we investigated the relationship between susceptibility to secondary HLH and TNF-alpha promoter polymorphisms to identify genetic factors of secondary HLH.
|
17166738 |
2006 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Similarly, there was no increased rate of TNFalpha-308A in all the lymphomas studied, irrespective of lineage.
|
17071494 |
2006 |
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, similar TTP expression in both groups correlated with an identical decay rate of TNF mRNA, which excludes this pathway for the higher LPS-induced TNF mRNA levels in PBC from lymphoma patients.
|
11956026 |
2002 |
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Frequent expression of the tumor necrosis factor receptor-associated factor 1 in latent membrane protein 1-positive posttransplant lymphoproliferative disease and HIV-associated lymphomas.
|
11567226 |
2001 |
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In contrast, the relative TNF mRNA amounts were significantly higher in lymphoma patients at 30 minutes (median 27.75 vs. 16.00; Mann-Whitney U-test p < 0.05), at 4 hours (52.00 vs. 31.00; p < 0.05), and at 24 hours (19.50 vs. 9.00; p < 0.05).
|
11274761 |
2001 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Our analysis of a series of AIDS lymphomas revealed that IFN-alpha selectively induced very high levels of the Death Receptor (DR) tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in HHV-8 positive PEL lines and primary tumor cells whereas little or no induction was observed in primary EBV+ AIDS lymphomas and EBV-Burkitt's lines.
|
11704827 |
2001 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We show here that murine TNF fused with CNGRC peptide (NGR-TNF), an aminopeptidase N (CD13) ligand that targets activated blood vessels in tumors, is 12-15 times more efficient than murine TNF in decreasing the tumor burden in lymphoma and melanoma animal models, whereas its toxicity is similar.
|
11062439 |
2000 |